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Pharmacokinetic Analysis of Carboplatin and Etoposide in a
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Cancer chemotherapy is not well established for patients on hemo-
dialysis (HD). A 77-year-old man on HD presented with small cell
lung cancer. He was treated with the combination of carboplatin and
etoposide while the pharmacokinetics of the drugs were monitored.
The patient showed a response with manageable toxicity and re-
mained progression free for at least 8 months. The area under the
concentration-time curve for each antitumor agent in the patient was
within the therapeutic range achieved in individuals with normal
renal function. Carboplatin and etoposide chemotherapy combined
with HD thus allowed the drugs to achieve an appropriate area under
the concentration-time curve and sufficient efficacy in a small cell
lung cancer patient with chronic renal failure.
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(J Thorac Oncol. 2008;3: 1073–1075)
The prognosis of patients with chronic renal failure hasimproved as a result of progress in hemodialysis (HD),
and opportunities to treat malignant tumors that develop in
such HD patients are increasing. However, little is known of
the safety or efficacy of chemotherapy for malignant tumors
in HD patients. We analyzed the pharmacokinetics of com-
bination chemotherapy with carboplatin (CBDCA) and eto-
poside in a patient with small cell lung cancer (SCLC)
undergoing HD.
CASE REPORT
A 77-year-old man with chronic renal failure due to
diabetic nephropathy presented with a mass in the left hilar
area in March 2007. The general condition of the patient, who
had undergone HD, three times a week, was fair, with
symptoms such as cough, weight loss, and fever being absent.
His Eastern Cooperative Oncology Group performance status
was 1. Computed tomography of the chest revealed a 45/33
mm mass in the lower left lobe as well as interstitial pneu-
monia in the lower left and lower right lobes. Histopathologic
analysis of a transbronchial biopsy specimen revealed SCLC.
No distant metastasis was detected on systemic examinations,
and the patient was diagnosed with limited-stage SCLC.
Laboratory testing revealed blood urea nitrogen and creati-
nine levels of 101 and 8.6 mg/dl, respectively. Other exam-
ined laboratory parameters were within normal limits, but
subsequent evaluation of serum tumor markers revealed an
increased level (18.2 ng/ml) of neuron-specific enolase,
which is not affected by renal function.1
Radiotherapy was not appropriate for the patient be-
cause of his bilateral interstitial pneumonia. Given his good
performance status and after obtaining informed consent, we
treated the patient with the combination of CBDCA and
etoposide (Figure 1). On day 1 of the treatment cycle, the
patient received an intravenous injection of etoposide (50
mg/m2) over 60 minutes followed by an intravenous injection
of CBDCA (250–275 mg/m2) also over 60 minutes. HD was
initiated 60 minutes after completion of CBDCA administra-
tion and was performed for 4 hours. On day 3, etoposide (50
mg/m2) was administered over 60 minutes and HD was
performed for 4 hours beginning 2 hours after completion of
etoposide injection. The doses of CBDCA and etoposide as
well as the timing of HD were based on previous studies.2–4
The treatment was well tolerated. Nonhematologic toxicities
such as nausea, vomiting, and fatigue were not observed. The
patient also did not experience neutoropenia or thrombocy-
topenia (Nadir neutrophil and platelet counts during 3 cycles
of chemotherapy were 2200/l and 15.5  104/l, respec-
tively). Prophylactic administration of granulocyte colony-
stimulating was not carried out. After three cycles of chemo-
therapy, each separated by an interval of 3 weeks, the tumor
had decreased in size and the serum neuron-specific enolase
level had decreased to within normal limits (6.3 ng/ml). The
patient remained progression free 8 months after the initiation
of treatment.
Pharmacokinetic analysis of CBDCA and etoposide
was performed for the first and third courses of chemother-
apy. Serial blood samples were collected 0, 1, 2, 3, 4, 5, 6, 24,
37, 41, 42, 49, 53, and 54 hours after completion of CBDCA
administration as well as 0, 2, 3, 4, 5, 6, 7, 25, 48, 50, 52, 54,
55, and 73 hours after completion of the first etoposide
administration. Each blood sample was analyzed for free
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platinum and etoposide (Figure 1) as described previously.5
In the first cycle, the area under the concentration-time curve
(AUC) was 4.10 minutes mg/ml for free platinum and 4401
and 3612 minutes g/ml for etoposide on days 1 and 3,
respectively. In the third course of chemotherapy, for which
the CBDCA dose was increased from 250 to 275 mg/m2, the
AUC of free platinum was 4.16 minutes mg/ml. The maximal
concentration and half-life of free platinum were 7.7 g/ml
and 2.51 hours in the first cycle and 9.4 g/ml and 1.93 hours
in the third cycle.
DISCUSSION
Many lung cancer patients undergoing HD as a result of
impaired renal function may be “undertreated” because che-
motherapy regimens are not well established for such indi-
viduals. The lack of pharmacokinetic data for most cytotoxic
agents in HD patients makes it difficult to administer chemo-
therapy effectively. Given his old age, bilateral interstitial
pneumonia, and renal dysfunction, the present patient might
have been considered too high a risk for chemotherapy and
recommended to receive best supportive care. However, tak-
ing into account the sensitivity of SCLC to platinum combi-
nation chemotherapy, we treated him with CBDCA and
etoposide while monitoring the pharmacokinetics of these
antitumor agents.
CBDCA is a less emetic and less nephrotoxic analog of
cisplatin and is preferred over cisplatin for use in patients
with renal insufficiency. The desired AUC for CBDCA can
be individualized with the use of Calvert’s formula on the
basis of individual renal function.6 In previous studies of
CBDCA-based chemotherapy in patients undergoing HD, a
CBDCA dose of 100 to 150 mg/body was chosen according
to this formula, with the glomerular filtration rate set to zero
because of the absence of renal function (Table 1).7–10 In
these studies, HD was performed 16 to 24 hours after com-
pletion of CBDCA administration, resulting in an AUC of
4.43 to 6.9 minutes mg/ml. More recently, administration of
a relatively high dose (300 mg/m2) of CBDCA with initiation
of HD 0.5 to 1.5 hours after completion of drug injection has
been shown to be feasible and effective in lung cancer
patients undergoing HD.2–4 However, the AUC of CBDCA in
these latter studies was not determined. In the present study,
we found that a CBDCA dose of 250 to 275 mg/m2 admin-
istered completely 1 hour before HD gave rise to an AUC for
free platinum of 4.10 to 4.16 minutes mg/ml, a therapeutic
blood level, consistent with the antitumor efficacy observed
FIGURE 1. Chemotherapy and hemodialy-
sis schedule as well as the plasma concen-
trations of free platinum and etoposide for
the proband. Data are for the first of three
cycles of chemotherapy. HD, hemodialysis;
CBDCA, carboplatin.
TABLE 1. Previous Studies of Carboplatin-Based Chemotherapy in Cancer Patients on Hemodialysis
Disease No. of Patients Carboplatin Dose
Interval Between Carboplatin
Infusion and Hemodialysis (h) AUC (min mg/ml)
Watanabe et al.7 Ovarian cancer 1 125 mg 16 4.43
Jeyabalan et al.8 Ovarian cancer 1 125 mg 24 N.D
Chatelut et al.9 Ovarian cancer 1 150 mg 24 6.06–6.70
Motzer et al.10 Germ cell tumor 2 100 mg/m2 24 6.7–6.9
Inoue et al.2 SCLC 3 300 mg/m2 1 N.D
Yanagawa et al.3 NSCLC/epipharynx ca 2 300 mg/m2 0.5 N.D
Haraguchi et al.4 SCLC 1 300 mg/m2 1.5 N.D
N.D, not determined; NSCLC, non-small cell lung cancer.
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in the previous studies2–4. Our presented study supports that
relatively high dose administration of CBDCA with initiation
of HD 1 hour after drug injection would be an alternative
strategy for patients with HD -dependent renal insufficiency.
Etoposide is active against various types of malignant
tumors, but its membrane permeability in HD remains un-
clear. The AUC range for etoposide in 13 patients with
normal renal function treated with this drug at a dose of 100
mg/m2 was previously shown to be 2291 to 6832 minutes
g/ml (Ref. 11). The present patient was treated with etopo-
side at 50 mg/m2 on days 1 and 3, with HD being initiated 2
hours after completion of the drug injection. The AUC of
etoposide was 3612 to 4401 minutes g/ ml, values that are
within the range achieved in patients with normal renal
function. Indeed, the combination chemotherapy in the pro-
band induced a tumor response that persisted for at least 8
months. Administration of etoposide at 100 mg/m2 on days 1,
3, and 5 in combination with cisplatin at 80 mg/m2 was
shown to be acceptable in 4 lung cancer patients with renal
dysfunction.12 In the previous study, HD was performed soon
after drug administration, resulting in an AUC for etoposide
of 4800 to 6204 minutes g/ml. Data from the previous
studies and our present patient thus indicate that etoposide
can be administered safely in HD patients.
The present case shows that CBDCA and etoposide
chemotherapy combined with HD resulted in AUCs for these
drugs within the therapeutic range in a SCLC patient with
chronic renal failure. Although further studies are needed, our
findings suggest that this regimen of combination chemother-
apy can be administered to lung cancer patients with renal
insufficiency.
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